Cargando…
Rate of Primary Refractory Disease in B and T-Cell Non-Hodgkin’s Lymphoma: Correlation with Long-Term Survival
BACKGROUND: Primary refractory disease is a main challenge in the management of non-Hodgkin’s Lymphoma (NHL). This survey was performed to define the rate of refractory disease to first-line therapy in B and T-cell NHL subtypes and the long-term survival of primary refractory compared to primary res...
Autores principales: | Tarella, Corrado, Gueli, Angela, Delaini, Federica, Rossi, Andrea, Barbui, Anna Maria, Gritti, Giuseppe, Boschini, Cristina, Caracciolo, Daniele, Bruna, Riccardo, Ruella, Marco, Gottardi, Daniela, Passera, Roberto, Rambaldi, Alessandro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4177839/ https://www.ncbi.nlm.nih.gov/pubmed/25255081 http://dx.doi.org/10.1371/journal.pone.0106745 |
Ejemplares similares
-
Primary Treatment Response Rather than Front Line Stem Cell Transplantation Is Crucial for Long Term Outcome of Peripheral T-Cell Lymphomas
por: Gritti, Giuseppe, et al.
Publicado: (2015) -
P110: Outcome of high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT) as first salvage treatment for relapsed or refractory classical Hodgkin Lymphoma (cHL) in the era of PET-adapted strategy among Italian centers
por: Viviani, Simonetta, et al.
Publicado: (2022) -
Evaluation of tenascin-C by tenatumomab in T-cell non-Hodgkin lymphomas identifies a new target for radioimmunotherapy
por: Gritti, Giuseppe, et al.
Publicado: (2018) -
Prognostic Impact of Baseline Immunologic Profile in Aggressive B-cell non-Hodgkin’s Lymphomas
por: Ramadan, Safaa, et al.
Publicado: (2021) -
Adoptive T-cell therapy for Hodgkin lymphoma
por: Ho, Carrie, et al.
Publicado: (2021)